Fabry Disease
Diagnostic Checklist
Use this tool to understand how Fabry disease is diagnosed

Could it be Fabry? Compare the symptoms, diagnostics and family history of your patient.
Symptoms
Does your patient present with any of the symptoms listed below? (check all that apply)
Diagnostics
Has your patient undergone any of these tests & procedures? (check all that apply)
Engagement of an expert centre for conclusive diagnosis. In the event of confirmed Fabry disease diagnosis, further monitoring of progress and organ screening is recommended.
Note: this listing of symptoms/findings and diagnostic tests may not be all-inclusive.
Fabry Disease Possible
Does your patient's medical or family history exhibit any of the following? (check all that apply)
Patient's Medical History
Family Medical History
Fabry Disease Probable
These tests can be used to confirm a Fabry disease diagnosis. Learn more about diagnosis
Dry blood test determining:
- The genetic mutation
- The level of α-galactosidase A (α-Gal A) activity
- The biomarker lyso-Gb3
Molecular genetic/ cytogenetic Fabry diagnosis from:
- EDTA blood test
- Serum
- Buccal swab

Could it be Fabry? Compare the symptoms, diagnostics and family history of your patient.
Symptoms
Does your patient present with any of the symptoms listed below? (check all that apply)
Diagnostics
Has your patient undergone any of these tests & procedures? (check all that apply)
Engagement of an expert centre for conclusive diagnosis. In the event of confirmed Fabry disease diagnosis, further monitoring of progress and organ screening is recommended.
Note: this listing of symptoms/findings and diagnostic tests may not be all-inclusive.
Fabry Disease Possible
Does your patient's medical or family history exhibit any of the following? (check all that apply)
Patient's Medical History
Family Medical History
Fabry Disease Probable
These tests can be used to confirm a Fabry disease diagnosis. Learn more about diagnosis
Dry blood test determining:
- The genetic mutation
- The level of α-galactosidase A (α-Gal A) activity
- The biomarker lyso-Gb3
Molecular genetic/ cytogenetic Fabry diagnosis from:
- EDTA blood test
- Serum
- Buccal swab

Could it be Fabry? Compare the symptoms, diagnostics and family history of your patient.
Symptoms
Does your patient present with any of the symptoms listed below? (check all that apply)
Diagnostics
Has your patient undergone any of these tests & procedures? (check all that apply)
Engagement of an expert centre for conclusive diagnosis. In the event of confirmed Fabry disease diagnosis, further monitoring of progress and organ screening is recommended.
Note: this listing of symptoms/findings and diagnostic tests may not be all-inclusive.
Fabry Disease Possible
Does your patient's medical or family history exhibit any of the following? (check all that apply)
Patient's Medical History
Family Medical History
Fabry Disease Probable
These tests can be used to confirm a Fabry disease diagnosis. Learn more about diagnosis
Dry blood test determining:
- The genetic mutation
- The level of α-galactosidase A (α-Gal A) activity
- The biomarker lyso-Gb3
Molecular genetic/ cytogenetic Fabry diagnosis from:
- EDTA blood test
- Serum
- Buccal swab

Could it be Fabry? Compare the symptoms, diagnostics and family history of your patient.
Symptoms
Does your patient present with any of the symptoms listed below? (check all that apply)
Diagnostics
Has your patient undergone any of these tests & procedures? (check all that apply)
Engagement of an expert centre for conclusive diagnosis. In the event of confirmed Fabry disease diagnosis, further monitoring of progress and organ screening is recommended.
Note: this listing of symptoms/findings and diagnostic tests may not be all-inclusive.
Fabry Disease Possible
Does your patient's medical or family history exhibit any of the following? (check all that apply)
Patient's Medical History
Family Medical History
Fabry Disease Probable
These tests can be used to confirm a Fabry disease diagnosis. Learn more about diagnosis
Dry blood test determining:
- The genetic mutation
- The level of α-galactosidase A (α-Gal A) activity
- The biomarker lyso-Gb3
Molecular genetic/ cytogenetic Fabry diagnosis from:
- EDTA blood test
- Serum
- Buccal swab

Could it be Fabry? Compare the symptoms, diagnostics and family history of your patient.
Symptoms
Does your patient present with any of the symptoms listed below? (check all that apply)
Diagnostics
Has your patient undergone any of these tests & procedures? (check all that apply)
Engagement of an expert centre for conclusive diagnosis. In the event of confirmed Fabry disease diagnosis, further monitoring of progress and organ screening is recommended.
Note: this listing of symptoms/findings and diagnostic tests may not be all-inclusive.
Fabry Disease Possible
Does your patient's medical or family history exhibit any of the following? (check all that apply)
Patient's Medical History
Family Medical History
Fabry Disease Probable
These tests can be used to confirm a Fabry disease diagnosis. Learn more about diagnosis
Dry blood test determining:
- The genetic mutation
- The level of α-galactosidase A (α-Gal A) activity
- The biomarker lyso-Gb3
Molecular genetic/ cytogenetic Fabry diagnosis from:
- EDTA blood test
- Serum
- Buccal swab

Could it be Fabry? Compare the symptoms, diagnostics and family history of your patient.
Symptoms
Does your patient present with any of the symptoms listed below? (check all that apply)
Diagnostics
Has your patient undergone any of these tests & procedures? (check all that apply)
Engagement of an expert centre for conclusive diagnosis. In the event of confirmed Fabry disease diagnosis, further monitoring of progress and organ screening is recommended.
Note: this listing of symptoms/findings and diagnostic tests may not be all-inclusive.
Fabry Disease Possible
Does your patient's medical or family history exhibit any of the following? (check all that apply)
Patient's Medical History
Family Medical History
Fabry Disease Probable
These tests can be used to confirm a Fabry disease diagnosis. Learn more about diagnosis
Dry blood test determining:
- The genetic mutation
- The level of α-galactosidase A (α-Gal A) activity
- The biomarker lyso-Gb3
Molecular genetic/ cytogenetic Fabry diagnosis from:
- EDTA blood test
- Serum
- Buccal swab

Could it be Fabry? Compare the symptoms, diagnostics and family history of your patient.
Symptoms
Does your patient present with any of the symptoms listed below? (check all that apply)
Diagnostics
Has your patient undergone any of these tests & procedures? (check all that apply)
Engagement of an expert centre for conclusive diagnosis. In the event of confirmed Fabry disease diagnosis, further monitoring of progress and organ screening is recommended.
Note: this listing of symptoms/findings and diagnostic tests may not be all-inclusive.
Fabry Disease Possible
Does your patient's medical or family history exhibit any of the following? (check all that apply)
Patient's Medical History
Family Medical History
Fabry Disease Probable
These tests can be used to confirm a Fabry disease diagnosis. Learn more about diagnosis
Dry blood test determining:
- The genetic mutation
- The level of α-galactosidase A (α-Gal A) activity
- The biomarker lyso-Gb3
Molecular genetic/ cytogenetic Fabry diagnosis from:
- EDTA blood test
- Serum
- Buccal swab
Could it be Fabry? Compare the symptoms, diagnostics and family history of your patient.
Kidneys
|
Eyes
Ears
|
Skin
Quality of Life
|
Nervous System
|
Cardiology
Cardiac abnormalities- Involvement of all cardiac structures3
- Angina pectoris, coronary artery disease, myocardial infarction occur3
- Arrhythmia—frequency increasing with age (permanent artificial pacing needed in 10%-20% of patients)3,8
- Left ventricular hypertrophy (LVH) in ~50% of patients3
- Other possible symptoms include trouble regulating blood pressure, poor cerebrovascular activity8
- Cardiovascular disease is a major cause of mortality
- TIA and stroke are common – often before Fabry diagnosis3
- Recurrence is common and associated with poor prognosis3
- White matter lesions have been associated with Fabry disease3
Fabry Diagnostic Checklist For Cardiologists
Compare the symptoms, diagnostics and family history of your patient.
Dermatology
Dermatological symptoms- Angiokeratomas are a hallmark of Fabry disease and an early clinical sign. Commonly occur around the lower trunk, also in the oral mucosa and conjunctiva.3,8
- Diffuse angiokeratomas tend to increase in number and size over time8
- Hypohidrosis, telangiectasia, and lymphedema are also common3
- Increasing recognition of facial dysmorphism3
Gastroenterology
GI symptoms- ~50% of patients with Fabry disease3
- Postprandial abdominal pain and diarrhea are common GI symptoms3
- Constipation, nausea, and vomiting are also common3
- Many affected individuals experience symptoms in childhood and have difficulty gaining weight and height8
Fabry Diagnostic Checklist For Gastroenterologists
Compare the symptoms, diagnostics and family history of your patient.
Nephrology
Accumulation of GL-3 within lysosomes of glomerular podocytes Renal dysfunction3,8- ~50% of patients with Fabry disease3
- Proteinuria is the most common symptom3
- Initial manifestations also include impaired glomerular filtration rate and tubular derangements8
- Eventual glomerular sclerosis, tubular atrophy, interstitial fibrosis may lead to kidney failure8
- Chronic kidney disease is the main cause of premature death in classic phenotype. Availability of dialysis and transplant has helped to extend life.8
Fabry Diagnostic Checklist For Nephrologists
Compare the symptoms, diagnostics and family history of your patient.
Neurology
Neurological symptoms- Most frequently reported symptoms in Fabry disease (~80% of patients). Neuropathic pain commonly affects the hands and feet3
- Early symptoms related to dysfunction of peripheral and autonomic nervous systems; late symptoms due to vascular complications of central nervous system8
- CNS symptoms increase with age8
- Burning/tingling pain—widespread but most frequent in hands/feet8
- Pain may be triggered by physical activity, cold/heat, fever, stress8
- Autonomic dysfunction—hypohidrosis, exercise intolerance, altered temperature sensitivity8
Fabry Diagnostic Checklist For Neurologists
Compare the symptoms, diagnostics and family history of your patient.
Opthalmology
Tortuosity of retinal vessels indicate cornea verticillataOcular symptoms
- Cornea verticillata (pale, spiral streaks or haze in the corneal epithelium) is a diagnostic criterion (>70% of patients)3,8,9
- Vessel tortuosity may represent a severe phenotype3
- Ophthalmic features in ~60% of children with Fabry disease3
- Vascular involvement is common in conjunctival blood vessels and retina, and reduced lacrimal secretions may occur8
- Ophthalmic manifestations do not usually lead to major visual impairment or symptoms9
Otolaryngology
Hearing lossAuditory and vestibular abnormalities
- Hearing loss (especially in the high tone range), tinnitus, and vertigo are common2,3
- Sudden deafness may also occur8
- ~16% of patients with clinically relevant hearing loss3
- Hearing loss correlates with neuropathic and vascular damage5
Psychiatry/Psychology
Quality of Life (QoL), depression, and psychosocial effects- Multiple disease symptoms can significantly influence patient quality of life3
- Results from a UK-based survey showed that ~ 46% of patients with Fabry disease experienced depression, 28% of whom could be considered clinically severe3,12
- Most common association with depression was neuropathic pain13
- Depression may be caused by coping with symptoms and/or cerebrovascular disease which can interfere with affective functioning and increase frequency/severity of depression13
- May be severe neuropsychological impairment due to decline in intellectual and global cognitive functioning13
Pulmonology
Pulmonary effects- Dyspnea with exercise, chronic couth/wheezing are frequent5
- Airway obstruction is common finding5, clinically presenting more like chronic obstructive pulmonary disease than asthma10
- Sleep-disordered breathing and obstructive sleep apnea is highly prevalent11
Click on a condition below to learn more:
References
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. Guidelines Catalog No. 030/134. Interdisziplinäre Leitlinie für die Diagnose und Therapie des Morbus Fabry.
Burlina AP, Sims KB, Politei JM, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11:61.
Di Bella G, Pizzino F, Minutoli F, et al. The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease. Eur Heart J Cardiovasc Imaging. 2014;15(12):1307-1315.
Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539-548.
Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease – recommendations of a European expert group. J Inherit Metab Dis. 2011;34(2):509-514.
Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.
Haas S, Lampl C. Morbus Fabry – Neurologische Klinik und Möglichkeiten der Therapie. J Neurol Neurochir Psychiatr. 2004;5(1):40-43.
Hoffmann B, Mayatepek E. Fabry disease – often seen, seldom diagnosed. Dtsch Arztebl Int. 2009;106(26):440-447.
Namdar M. Electrocardiographic changes and arrhythmia in Fabry disease. Front Cardiovasc Med. 2016;3:1-6.
Niemann M, Liu D, Hu K, et al. Prominent papillary muscles in Fabry disease: a diagnostic marker? Ultrasound Med Biol. 2011;37(1):37-43.
Parchoux B, Guibaud P, Maire I, et al. Fabry‘s disease. Initial nephrogenic diabetes insipidus in children. Pediatrie. 1978;33(8):757-765. [French]
Pisani A, Petruzzelli Annicchiarico L, Pellegrino A, et al. Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrol Dial Transplant. 2017 March 28. (ePub ahead of print)
References
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. Guidelines Catalog No. 030/134. Interdisziplinäre Leitlinie für die Diagnose und Therapie des Morbus Fabry.
Burlina AP, Sims KB, Politei JM, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11:61.
Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539-548.
Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease – recommendations of a European expert group. J Inherit Metab Dis. 2011;34(2):509-514.
Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.
Haas S, Lampl C. Morbus Fabry – Neurologische Klinik und Möglichkeiten der Therapie. J Neurol Neurochir Psychiatr. 2004;5(1):40-43.
Hoffmann B, Mayatepek E. Fabry disease – often seen, seldom diagnosed. Dtsch Arztebl Int. 2009;106(26):440-447.
Parchoux B, Guibaud P, Maire I, et al. Fabry‘s disease. Initial nephrogenic diabetes insipidus in children. Pediatrie. 1978;33(8):757-765. [French]
Pisani A, Petruzzelli Annicchiarico L, Pellegrino A, et al. Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrol Dial Transplant. 2017 March 28. (ePub ahead of print)
References
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. Guidelines Catalog No. 030/134. Interdisziplinäre Leitlinie für die Diagnose und Therapie des Morbus Fabry.
Burlina AP, Sims KB, Politei JM, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11:61.
Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539-548.
Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease – recommendations of a European expert group. J Inherit Metab Dis. 2011;34(2):509-514.
Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.
Haas S, Lampl C. Morbus Fabry – Neurologische Klinik und Möglichkeiten der Therapie. J Neurol Neurochir Psychiatr. 2004;5(1):40-43.
Hoffmann B, Mayatepek E. Fabry disease – often seen, seldom diagnosed. Dtsch Arztebl Int. 2009;106(26):440-447.
Parchoux B, Guibaud P, Maire I, et al. Fabry‘s disease. Initial nephrogenic diabetes insipidus in children. Pediatrie. 1978;33(8):757-765. [French]
Pereira EM, da Silva AS, Labilloy A, do Monte Neto JT, do Monte SJ. Podocyturia in Fabry disease. J Bras Nefrol. 2016;38(1):49-53.
Pisani A, Petruzzelli Annicchiarico L, Pellegrino A, et al. Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrol Dial Transplant. 2017 March 28. (ePub ahead of print)
References
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. Guidelines Catalog No. 030/134. Interdisziplinäre Leitlinie für die Diagnose und Therapie des Morbus Fabry.
Burlina AP, Sims KB, Politei JM, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11:61.
Domínguez RO, Michref A, Tanus E, Amartino H. Síndrome de piernas inquietas en la enfermedad de Fabry: asociación con dolor neuropático. Rev Neurol. 2007;45(8):474-478.
Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539-548.
Fellgiebel A, Keller I, Marin D, et al. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology. 2009;72(1):63-68.
Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease – recommendations of a European expert group. J Inherit Metab Dis. 2011;34(2):509-514.
Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.
Haas S, Lampl C. Morbus Fabry – Neurologische Klinik und Möglichkeiten der Therapie. J Neurol Neurochir Psychiatr. 2004;5(1):40-43.
Hoffmann B, Mayatepek E. Fabry disease – often seen, seldom diagnosed. Dtsch Arztebl Int. 2009;106(26):440-447.
Joseph FG, Scolding NJ. Cerebral vasculitis: a practical approach. Pract Neurol. 2002;2(2):80-93.
Mohanraj R, Leach JP, Broome JC, Smith DF. Neurological presentation of Fabry's disease in a 52 year old man. J Neurol Neurosurg Psychiatry. 2002;73(3):340-342.
Parchoux B, Guibaud P, Maire I, et al. Fabry‘s disease. Initial nephrogenic diabetes insipidus in children. Pediatrie. 1978;33(8):757-765. [French]
Pisani A, Petruzzelli Annicchiarico L, Pellegrino A, et al. Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrol Dial Transplant. 2017 March 28. (ePub ahead of print)
Politei JM, Bouhassira D, Germain DP, et al. Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther. 2016;22(7):568-576.
Sack KE. When vasculitis is not vasculitis. Hosp Practice. 1993;28(7):94-103.
Salviati A, Burlina AP, Borsini W. Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy. Neurol Sci. 2010;31(3):299-306.
References
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. Guidelines Catalog No. 030/134. Interdisziplinäre Leitlinie für die Diagnose und Therapie des Morbus Fabry.
Burlina AP, Sims KB, Politei JM, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11:61.
Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539-548.
Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease – recommendations of a European expert group. J Inherit Metab Dis. 2011;34(2):509-514.
Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.
Haas S, Lampl C. Morbus Fabry – Neurologische Klinik und Möglichkeiten der Therapie. J Neurol Neurochir Psychiatr. 2004;5(1):40-43.
Hoffmann B, Mayatepek E. Fabry disease – often seen, seldom diagnosed. Dtsch Arztebl Int. 2009;106(26):440-447.
James RA, Singh-Grewal D, Lee S-J, McGill J, Adib N. Lysosomal storage disorders: a review of the musculoskeletal features. J Paed Child Health. 2016;52(3):262-271.
Parchoux B, Guibaud P, Maire I, et al. Fabry‘s disease. Initial nephrogenic diabetes insipidus in children. Pediatrie. 1978;33(8):757-765. [French]
Pisani A, Petruzzelli Annicchiarico L, Pellegrino A, et al. Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrol Dial Transplant. 2017 March 28. (ePub ahead of print)
Samiy N. Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol. 2008;53(4):416-423.
Torralba-Cabeza M-A, Olivera S, Hughes DA, Pastores GM, Nuviala Mateo R, Pérez-Calvo J-I. Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease. Mol Genet Metab. 2011;104(3):301-307.
References
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. Guidelines Catalog No. 030/134. Interdisziplinäre Leitlinie für die Diagnose und Therapie des Morbus Fabry.
Burlina AP, Sims KB, Politei JM, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11:61.
Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539-548.
Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease – recommendations of a European expert group. J Inherit Metab Dis. 2011;34(2):509-514.
Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.
Haas S, Lampl C. Morbus Fabry – Neurologische Klinik und Möglichkeiten der Therapie. J Neurol Neurochir Psychiatr. 2004;5(1):40-43.
Hajas A, Grubits J, Varga Z. Neurophysiologic examinations in patients with Fabry-Anderson disease. Clin Ther. 2012;34(4 suppl):e19-e20.
Hoffmann B, Mayatepek E. Fabry disease – often seen, seldom diagnosed. Dtsch Arztebl Int. 2009;106(26):440-447.
James RA, Singh-Grewal D, Lee S-J, McGill J, Adib N. Lysosomal storage disorders: a review of the musculoskeletal features. J Paed Child Health. 2016;52(3):262-271.
Parchoux B, Guibaud P, Maire I, et al. Fabry‘s disease. Initial nephrogenic diabetes insipidus in children. Pediatrie. 1978;33(8):757-765. [French]
Pisani A, Petruzzelli Annicchiarico L, Pellegrino A, et al. Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrol Dial Transplant. 2017 March 28. (ePub ahead of print)
Politei JM, Bouhassira D, Germain DP, et al. Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther. 2016;22(7):568-576.
Politei J, Remondino G, Heguilen R, Wallace E, Durand C, Schenone A. When arthralgia is not arthritis. Eur J Rheumatol. 2016;3(4)182-184.
Sack KE. When vasculitis is not vasculitis. Hosp Practice. 1993;28(7):94-103.
Salviati A, Burlina AP, Borsini W. Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy. Neurol Sci. 2010;31(3):299-306.
Schiffmann R, Moore DF. Neurological manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, eds. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006.
References
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. Guidelines Catalog No. 030/134. Interdisziplinäre Leitlinie für die Diagnose und Therapie des Morbus Fabry.
Burlina AP, Sims KB, Politei JM, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11:61.
Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539-548.
Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease – recommendations of a European expert group. J Inherit Metab Dis. 2011;34(2):509-514.
Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.
Haas S, Lampl C. Morbus Fabry – Neurologische Klinik und Möglichkeiten der Therapie. J Neurol Neurochir Psychiatr. 2004;5(1):40-43.
Hajas A, Grubits J, Varga Z. Neurophysiologic examinations in patients with Fabry-Anderson disease. Clin Ther. 2012;14(4 suppl):e19-e20.
Hoffmann B, Mayatepek E. Fabry disease – often seen, seldom diagnosed. Dtsch Arztebl Int. 2009;106(26):440-447.
James RA, Singh-Grewal D, Lee S-J, McGill J, Adib N. Lysosomal storage disorders: a review of the musculoskeletal features. J Paed Child Health. 2016;52(3):262-271.
Parchoux B, Guibaud P, Maire I, et al. Fabry‘s disease. Initial nephrogenic diabetes insipidus in children. Pediatrie. 1978;33(8):757-765. [French]
Pisani A, Petruzzelli Annicchiarico L, Pellegrino A, et al. Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrol Dial Transplant. 2017 March 28. (ePub ahead of print)
Politei JM, Bouhassira D, Germain DP, et al. Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther. 2016;22(7):568-576.
Politei J, Remondino G, Heguilen R, Wallace E, Durand C, Schenone A. When arthralgia is not arthritis. Eur J Rheumatol. 2016;3(4)182-184.
Sack KE. When vasculitis is not vasculitis. Hosp Practice. 1993;28(7):94-103.